Background: Identifying influences on disability accumulation in multiple sclerosis (MS), including modifiable factors other than the core features of disease itself, is vital for clinical care, but has often relied on instruments with acknowledged psychometric shortcomings. We model MS disability using the WHO Disability Assessment Schedule (WHODAS) 2.0, a validated measure based on the WHO's biopsychosocial model and sensitive to the breadth of disability-related domains important to people, to investigate the factors associated with its trajectory after diagnosis.

Methods: In a model allowing individual trajectories to vary around the population mean, we analysed the WHODAS 2.0, transforming it from ordinal raw scores to interval latent estimates via the Rasch Measurement Model (operational range 0 (low) to 128 (high disability)), across up to 6 surveys, from time of diagnosis to 24 years hence, by 5210 adults with MS from the UK's Trajectories of Outcome in Neurological Conditions-MS (TONiC-MS) longitudinal cohort study.

Results: Whilst disability rose, on average, across the disease course, and was higher for people with progressive onset MS (mean difference (MD) 14.55, 95 % confidence interval (CI) 12.56, 16.54), there was considerable variability between people in both their level of disability at time of diagnosis (with the WHODAS 2.0 scores of 90 % of people with MS expected to lie between 1.63 to 61.90) and in their subsequent trajectories. We found higher education was associated with lower disability (MD -5.81, 95 % CI -7.46, -4.16) and also delayed disability progression. However, further analyses indicated that the effect of education may be partially-mediated by self-efficacy. Higher levels of self-efficacy were associated with lower disability, and this effect was greater for those with lower education. In addition, the WHODAS 2.0 is sensitive to facets affected by depression, including cognition and participation in community activities, and we found greater depression to be associated with higher disability (MD 7.98, 95 % CI 7.05, 8.91). Both a higher number of comorbidities, and smoking, were associated with greater disability, especially early in the disease course. Higher disability was also found in those: not in work (MD 15.42, 95 % CI 14.24, 16.59) and more fatigued (5.83, 95 % CI 5.46, 6.21 per 1SD increase on Neurological Fatigue Index MS). Our results also indicated within-individual variability was greatest in those recorded as relapsing remitting at study entry, compared to those recorded as having progressive MS.

Conclusion: The interplay between self-efficacy, education and disability reinforces the importance of interventions seeking to enhance self-efficacy. Our results additionally support early monitoring and targeting of comorbidities and smoking, which could reduce disability progression. The associations of time-varying depression and fatigue with disability also offer important opportunities for treatment. Characterising disability progression via validated measures provides information, targets for health promotion and indicators of groups warranting closer monitoring.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2024.106228DOI Listing

Publication Analysis

Top Keywords

disability progression
16
disability
16
multiple sclerosis
8
longitudinal cohort
8
time diagnosis
8
disease course
8
course higher
8
associated lower
8
lower disability
8
higher disability
8

Similar Publications

Background: Gastric cancer (GC) is a common malignancy of the digestive system, with significant geographical variation in its disease burden.

Methods: This study used data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 to analyze three key indicators: incidence, mortality, and disability-adjusted life years (DALYs). Initially, a detailed analysis of the GC burden was conducted from global, regional, national, gender, and age perspectives.

View Article and Find Full Text PDF

Background: Angelman syndrome (AS), a severe neurodevelopmental disorder resulting from the loss of the maternal UBE3A gene, is marked by changes in the brain's white matter (WM). The extent of WM abnormalities seems to correlate with the severity of clinical symptoms, but these deficits are still poorly characterized or understood. This study provides the first large-scale measurement of WM volume reduction in children with AS.

View Article and Find Full Text PDF

Plant-derived compounds and neurodegenerative diseases: Different mechanisms of action with therapeutic potential.

Neuroscience

December 2024

Laboratorio de Mecanismos de Neurodegeneración y Neuroprotección, Departamento de Neurobiología y Neuropatología, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay; Neuroactive Natural Compounds UNESCO Chair, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay. Electronic address:

Neurodegenerative diseases are a group of disorders characterized by progressive degeneration of discrete groups of neurons causing severe disability. The main risk factor is age, hence their incidence is rapidly increasing worldwide due to the rise in life expectancy. Although the causes of the disease are not identified in about 90% of the cases, in the last decades there has been great progress in understanding the basis for neurodegeneration.

View Article and Find Full Text PDF

Incidence, mortality, and global burden of retinoblastoma in 204 countries worldwide from 1990 to 2021: Data and systematic analysis from the Global Burden of Disease Study 2021.

Neoplasia

December 2024

Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou, Zhejiang, China. Electronic address:

Background: Retinoblastoma (Rb), the primary intraocular malignancy in children, poses significant risks, yet its overall burden remains inadequately assessed. This study aims to analyze global Rb trends using Global Burden of Disease, Injuries, and Risk Factors study (GBD) 2021 data.

Methods: GBD 2021 data was analyzed to assess Rb incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021.

View Article and Find Full Text PDF

Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered?

Paediatr Drugs

December 2024

Division of Neurology, Department of Pediatrics, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.

Pediatric-onset multiple sclerosis (POMS) refers to multiple sclerosis with onset before 18 years of age. It is characterized by a more inflammatory course, more frequent clinical relapses, and a greater number of magnetic resonance imaging (MRI) lesions compared with adult-onset MS (AOMS), leading to significant impacts on both disability progression and cognitive outcomes in affected individuals. Managing POMS presents distinct challenges due to the unique needs of pediatric patients and the limited number of disease-modifying therapies (DMTs) approved for pediatric use.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!